Alpha 2.0
Login Register
» Authors » H W M van Laarhoven

H W M van Laarhoven

Explore the profile of H W M van Laarhoven including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 123
Citations 2087
Followers 0
Related Specialties
Oncology
General Medicine
Critical Care
Top 10 Co-Authors
M I van Berge Henegouwen
M C C M Hulshof
N Haj Mohammad
J W Wilmink
S S Gisbertz
M G H van Oijen
M G Besselink
A Heerschap
R H A Verhoeven
M A G Sprangers
Published In
Neth J Med
Support Care Cancer
BMC Cancer
Ann Oncol
Trials
Affiliations
Soon will be listed here.
Recent Articles
1.
Changes in perception of prognosis in the last year of life of patients with advanced cancer and its associated factors: Longitudinal results of the eQuiPe study
Versluis M, van de Poll-Franse L, Zijlstra M, van Laarhoven H, Vreugdenhil G, Henselmans I, et al.
Palliat Med . 2024 Dec; 39(2):277-285. PMID: 39629742
Background: Many patients with advanced cancer are unaware of their limited prognosis, however little is known about the change in awareness during the last year of their lives. Aim: To...
2.
Evaluating the Impact of Post-Esophagectomy Exercise on 2- and 5-Yr Survival: Findings from the PERFECT Trial
Binyam D, van Vulpen J, VAN Vulpen J, van Hillegersberg R, van Hillegersberg R, Ruurda J, et al.
Med Sci Sports Exerc . 2024 Sep; 57(2):327-336. PMID: 39293388
Purpose: Despite recent treatment advances, esophageal cancer still has poor survival and a high morbidity. Exploratory evidence suggests that exercise can reduce cancer-related mortality and recurrence rates. Here, we investigated...
3.
Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within...
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jul; 25(1):456. PMID: 38970096
No abstract available.
4.
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jun; 25(1):401. PMID: 38902836
Background: Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most patients experience local and/or distant PDAC recurrence...
5.
The narrow road to expanded access
Post H, Schutte T, Voortman J, Bartelink I, van Laarhoven H, Crul M
J Cancer Policy . 2024 Jun; 41:100490. PMID: 38849113
No abstract available.
6.
Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study
Gehrels A, Wagner A, Besselink M, Verhoeven R, van Eijck C, van Laarhoven H, et al.
Eur J Cancer . 2024 May; 206:114117. PMID: 38781719
Introduction: Sex and gender are modulators of health and disease and may have impact on treatment allocation and survival in patients with cancer. In this study, we analyzed the impact...
7.
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review
Bos J, Groen-van Schooten T, Brugman C, Jamaludin F, van Laarhoven H, Derks S
Cancer Treat Rev . 2024 Apr; 127:102737. PMID: 38669788
Background: Gastric cancer (GC), known for its unfavorable prognosis, has been classified in four distinct molecular subtypes. These subtypes not only exhibit differences in their genome and transcriptome but also...
8.
Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial)
van de Water L, Kuijper S, Henselmans I, van Alphen E, Kooij E, Calff M, et al.
EClinicalMedicine . 2023 Oct; 64:102244. PMID: 37781156
Background: For cancer patients to effectively engage in decision making, they require comprehensive and understandable information regarding treatment options and their associated outcomes. We developed an online prediction tool and...
9.
Standard versus prolonged intervals to surgery in resectable esophageal cancer: does timing matter?
Derks S, van Laarhoven H
Ann Oncol . 2023 Sep; 34(11):960-961. PMID: 37734663
No abstract available.
10.
F-FDG-PET/CT to Detect Pathological Complete Response After Neoadjuvant Treatment in Patients with Cancer of the Esophagus or Gastroesophageal Junction: Accuracy and Long-Term Implications
van der Aa D, Gisbertz S, Anderegg M, Lagarde S, Klaassen R, Meijer S, et al.
J Gastrointest Cancer . 2023 Jul; 55(1):270-280. PMID: 37393217
Purpose: The curative strategy for patients with esophageal cancer without distant metastases consists of esophagectomy with preceding chemo(radio)therapy (CRT). In 10-40% of patients treated with CRT, no viable tumor is...